top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
ATM Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
JERUSALEM, October 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Oct 30, 2023
Former U.S. Commissioner of FDA Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
JERUSALEM, October 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Oct 24, 2023
Alpha Tau Medical to Participate in June Investor Conferences
JERUSALEM, May 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 25, 2023
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first...
May 24, 2023
Alpha Tau Announces Publication: US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
- The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or...
May 11, 2023
Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day
JERUSALEM, May 03, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 4, 2023
Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit
JERUSALEM, March 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Mar 30, 2023
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank
JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer...
Mar 12, 2023
Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update
- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health...
Mar 10, 2023
Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial -First...
Mar 9, 2023
bottom of page